HER2 3+ expression was found in 19% (18/93) of the bladder cancers, comprised of 29% (nine of 31) high-grade NMIBCs and 36% (nine of 25) MIBCs (Table 1). This evidence concerns the gene ERBB2 and urinary bladder carcinoma.